Stock image

May 14, 2012 — Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this, in turn, can lead to an under-dose of radiation to the tumor or a potentially toxic overdose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place.

May 14, 2012 — U-Systems, a leader in automated breast ultrasound, announced today it has received a PMA approvable letter from the U.S. Food and Drug Administration (FDA) for the company’s somo•v automated breast ultrasound system (ABUS). The somo•v ABUS system is the first ultrasound device to receive an approval recommendation from an FDA Advisory Panel and an approvable letter for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue.

May 14, 2012 — Viztek announced the availability of its integrated mammography suite, Opal-Mammo. The women’s health solution features a multi-modality mammography viewer that offers streamlined management of high-resolution images.

May 14, 2012 — Lantheus Medical Imaging Inc. announced new manufacturing and supply agreements with Jubilant HollisterStier LLC (JHS). Under separate agreements, JHS will manufacture Cardiolite (kit for the preparation of technetium Tc99m sestamibi for injection) products and Neurolite (kit for the preparation of technetium Tc99m bicisate for injection), each for an initial term of five years and each with an option to renew for an additional five years thereafter.

May 14, 2012 — GE Healthcare introduced a new version of its Vscan pocket-sized visualization tool, developed to deliver imaging capabilities at the point of care. Based on feedback from current Vscan users, the new version features extended battery life, a more intuitive user interface and enhanced reporting capabilities.


May 14, 2012 — Using a concentrated, highly targeted dose of radiation to the breast has equally as good results as irradiating the whole area, with no adverse effects on survival and a much better cosmetic outcome, Hungarian researchers have found. Reporting the 10-year results of a randomised trial, Professor Csaba Polgár, M.D., director of the Centre for Radiotherapy, National Institute of Oncology, Budapest, told the World Congress of Brachytherapy (WCB) that he believes accelerated partial breast irradiation (APBI) could be offered to many more breast cancer patients, resulting in fewer side effects and major cost savings to healthcare systems.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now